cancer care in the time of covid 19 whitepaper

The coronavirus outbreak has affected thousands of people in at least 186 countries which has also affected the cancer care delivery system apart from affecting the overall health system. Cancer patients are more susceptible to coronavirus infection than individuals without cancer as they are in an immunosuppressive state caused due to the malignancy and anticancer treatments like the chemotherapy and the radiation therapy.

The purpose of this whitepaper is to represent an overview of the current cancer therapy scenario in the time of COVID-19. It is giving its readers a sneak peek into the world of the healthcare providers and human resource management systems, the risks, the challenges and the hurdles faced and how the global healthcare system is overcoming it.

Through this whitepaper, DelveInsight has showcased a view into the different guidelines, regulations and solutions implemented by the healthcare management systems across the globe to operate and execute the successful management and care of the cancer patients during the pandemic.

The emergence of the COVID-19 pandemic brought about a seismic shift in global healthcare systems, stretching their capacity and reshaping how care is delivered across all specialties. Among the most severely impacted was cancer care, where delays, disruptions, and resource reallocations significantly altered diagnosis, treatment, and support mechanisms for millions of patients worldwide. “Cancer Care in the Time of COVID” is a story of unprecedented challenge—yet also of innovation, resilience, and the urgent need for system-wide adaptability.